Patient and Caregiver Preferences for Once-Weekly Injection Devices for the Treatment of Growth Hormone Deficiency.
Patients and caregivers prioritize less injection pain and ease of use when choosing long-acting growth hormone treatments, with a significant preference for the somapacitan-beco device.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study assessed patient and caregiver preferences for once-weekly injection devices for growth hormone deficiency (GHD). A total of 100 participants, including adults, caregivers, and adolescent/caregiver dyads, completed a survey focused on the attributes of long-acting growth hormone analogues (LA-GHA). The most important attributes identified were postinjection pain (27%), the number of injections needed for a full dose (23%), and preparation time (16%).
Abstract
<h4>Context</h4>Once-weekly long-acting growth hormone (GH) analogue (LA-GHA) treatments offer an alternative to once-daily GH injections for the treatment of children and adults with GH deficiency (GHD). With these new LA-GHA options, it is important to understand patients' and caregivers' treatment preferences.<h4>Objective</h4>This work aimed to understand the injection/device attributes important to patients with GHD and caregivers when choosing LA-GHA treatment options.<h4>Methods</h4>In this cross-sectional study, a targeted literature review and qualitative interviews informed the development of an online survey. The survey included a discrete choice experiment, comprising a series of choice tasks. Respondents selected between hypothetical, experimentally designed, once-weekly LA-GHA device features corresponding to currently available devices. Study participants were patients/caregivers in the United States, self-reporting a GHD diagnosis and current short-acting GH injection use: adults (aged ≥18 years), caregivers of children (aged 3-11 years), and dyads of adolescents (aged 12-17 years) and their caregivers.<h4>Results</h4>In total, 100 participants completed the survey: 50 adults, 25 caregivers, and 25 adolescent/caregiver dyads. Overall, the most important LA-GHA attributes identified were postinjection pain (27%), the number of injections needed for 1 full dose (23%), and the time needed to prepare the device before each injection (16%). The profile similar to somapacitan-beco had the highest predicted choice probability (82%) compared with the profiles similar to lonapegsomatropin-tcgd (16%) and somatrogon-ghla (2%).<h4>Conclusion</h4>Understanding patient and caregiver preferences for LA-GHA devices with less injection pain and greater ease of use highlights the value of shared decision-making, potentially leading to better treatment adherence and subsequent clinical outcomes.
Background
The paper addresses the preferences of patients and caregivers regarding injection devices used for growth hormone deficiency treatment. Prior research has indicated that device usability can significantly impact treatment adherence and satisfaction. Understanding these preferences is crucial for optimizing treatment regimens and enhancing patient outcomes.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.